Story · Medicine & Biotech
Onvansertib Receives FDA Fast Track Designation in RAS-Mutated Colorectal Cancer
1 outlet · first reported by OncoDaily on
Cardiff Oncology announced on November 16, 2026, that the FDA granted Fast Track designation to onvansertib with FOLFIRI and bevacizumab for first-line treatment of adults with KRAS- or NRAS-mutated metastatic (OncoDaily)
Coverage, in order
-
Onvansertib Receives FDA Fast Track Designation in RAS-Mutated Colorectal CancerCardiff Oncology announced on November 16, 2026, that the FDA granted Fast Track designation to onvansertib with FOLFIRI and bevacizumab for first-line treatment of adults with KRAS- or NRAS-mutated metastatic
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.